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Abstract In vitro phosphorylation of recombinant wild-type
2N4R tau and FTDP-17 exonic mutant forms P301L, V337M
and R406W by glycogen synthase kinase 3L (GSK3L) was
examined by two dimensional phosphopeptide mapping analysis
on thin layer cellulose plates. Comparison of these peptide maps
with those generated from wild-type 1N4R tau isoform from
which the phosphopeptide constituents and sites of phosphoryla-
tion had been determined previously, enabled us to monitor
directly changes in phosphorylation of the individual tau proteins.
No differences were found in the phosphorylation of wild-type,
P301L or V337M tau by GSK3L but the R406W mutant showed
at least two clear differences from the other three tau proteins.
The peptides, identified by mass spectrometry corresponding to
phosphorylation at both threonine 231 and serine 235 (spot 3),
serines 396, 400 and 404 (spot 6a) and serines 195 and 199 (spot
6b) were absent from the R406W peptide map. The findings
imply that the R406W mutation in tau exerts long-range
conformational effects on the structure of tau. ß 2001 Pub-
lished by Elsevier Science B.V. on behalf of the Federation of
European Biochemical Societies.
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1. Introduction
Frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) is a group of inherited dementias
characterised clinically by behavioural and cognitive changes
accompanied by motor disorder. At autopsy, all patients with
FTDP-17 have pronounced frontotemporal atrophy, with loss
of neuronal cells, grey and white matter gliosis and super¢cial
spongiform changes [1]. The discovery of up to 20 di¡erent
exonic and intronic mutations in the gene encoding the micro-
tubule-associated protein tau, in over 40 families with FTDP-
17, has now con¢rmed the tau gene as the disease locus [1^5].
Neuropathologically FTDP-17 is one of a number of neu-
rodegenerative diseases collectively known as ‘tauopathies’ in-
cluding Alzheimer’s disease, Pick’s disease, progressive supra-
nuclear palsy and corticobasal degeneration that are
characterised by the presence of intracellular accumulations
of tau protein in a hyperphosphorylated state [6,7]. Tau mu-
tations in FTDP-17 fall into two major categories, exonic
missense mutations which are close to the mictrotubule bind-
ing domains and intronic mutations in the intron adjacent to
exon 10. There is some genotype^phenotype correlation in
FTDP-17 as the site of the mutations in exon 10 or in the
intron following exon 10 leads to a ¢lamentous neuronal and
glial cell tau pathology [8^10]. In exon 10 mutations, the ¢l-
aments are narrow twisted ribbons consisting predominantly
of tau isoforms with four microtubule binding repeats [10]
whereas in the case of the intronic mutations, the ¢laments
are wide twisted ribbons containing exclusively four repeat tau
isoforms [8]. On the other hand missense mutations outside
exon 10 lead to a predominantly neuronal pathology and the
tau ¢laments are paired helical ¢laments (PHFs) and straight
¢laments consisting of all six tau isoforms [11,12].
The role of tau in promoting microtubule growth and
stability has been well documented [13,14] and hyperphos-
phorylation of tau is known to reduce the ability of tau to
bind to and stabilise microtubules [15]. Several candidate ki-
nases have been identi¢ed which can phosphorylate tau in
vitro [16] including the proline-directed kinase glycogen syn-
thase kinase 3L (GSK3L) [17^20]. GSK3L has also been
shown to phosphorylate tau in cells [21] and in neurones in-
hibition of GSK3L with lithium or via insulin signalling re-
duces tau phosphorylation, providing evidence that GSK3L is
a physiological, if not the only, tau kinase [22^24].
Previous reports using immunoblotting suggested that one
mutation in tau (R406W) had the e¡ect of reducing tau phos-
phorylation in cells [25,26,32]. This was surprising given that
the aggregated tau in FTDP-17 is highly phosphorylated. In
order to examine this further we therefore studied the e¡ects
of three of the FTDP-17 missense mutations of tau, namely
P301L, V337M and R406W, on the in vitro phosphorylation
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of the largest isoform of tau (2N4R) by GSK3L using two
dimensional phosphopeptide mapping and nanoelectrospray
mass spectrometry (nanoES-MS) to directly monitor changes
in phosphorylation.
2. Materials and methods
2.1. Expression and puri¢cation of recombinant human tau
Recombinant full-length human wild-type (wt) and FTDP-17 mu-
tant tau cDNA with two N-terminal inserts and four repeat domains,
2N4R wt, P301L, V337M, R406W, in pET30a bacterial expression
vectors were used to transform Escherichia coli BL21-DE3 competent
cells. Tau protein expression was induced with 0.5 mM isopropyl-L-D-
thiogalactopyranoside for 2 h at 37‡C and puri¢ed essentially by the
method previously described [27]. Bacterial cells were collected by
centrifugation at 6000Ugav for 15 min at 4‡C and the cell pellet
washed once in 50 mM MES bu¡er pH 6.5. Washed cell pellet was
resuspended in 50 mM MES bu¡er pH 6.5 containing 1 mM dithio-
threitol (DTT), 1 mM phenylmethylsulphonyl£uoride (PMSF), 1 mM
EDTA, 10 mM NaF and 20 mM sodium pyrophosphate by hand
homogenisation before lysing the cells by sonication (VibraCell Sonics
and Materials, USA) for 6U30 s with 30 s on ice between sonications.
Unbroken cells and cell debris were pelleted by centrifugation at
15 000Ugav for 20 min at 4‡C. The supernatant was adjusted to 0.5
M NaCl and boiled for 10 min before centrifuging at 100 000Ugav for
2 h at 4‡C to collect the precipitated protein. Tau-enriched super-
natant was saturated to 45% (w/v) by the addition of ammonium
sulphate, stirring on ice for 1 h to precipitate the tau protein. Tau
protein was collected by centrifugation at 18 000Ugav for 20 min at
4‡C and the precipitated protein resuspended in 50 mM MES bu¡er
pH 6.5 containing 1 mM DTT and 1 mM PMSF prior to dialysing
overnight at 4‡C against at least two changes of the same bu¡er.
Anion exchange chromatography on a Mono S FPLC column was
then used as the ¢nal step to purify the tau protein. Aliquots of the
various major puri¢cation steps were analysed by sodium dodecyl
sulphate^polyacrylamide gel electrophoresis (SDS^PAGE) (10% w/v
acrylamide SDS^PAGE) followed by transfer of the resolved proteins
onto nitrocellulose paper and protogold staining (British Biocell In-
ternational, UK).
Puri¢ed tau protein was quanti¢ed by 10% w/v acrylamide SDS^
PAGE followed by Coomassie brilliant blue staining against a bovine
serum albumin standard of known concentration.
2.2. In vitro phosphorylation of recombinant human tau
(wt, P301L, V337M and R406W) with GSK3L
Puri¢ed recombinant human tau (wt, P301L, V337M and R406W)
protein was phosphorylated by rat GSK3L as described below. The
rat GSK3L was supplied by J.R. Woodgett, Ontario Cancer Institute,
Canada, in a recombinant baculovirus and puri¢ed by the method of
Hughes et al. [28] incorporating the modi¢cation of Utton et al. [29].
1^2 Wg of tau protein was phosphorylated overnight by incubation
at 30‡C in 40 Wl of 20 mM HEPES bu¡er pH 7.4 containing 10 mM
MgCl2, 1 mM DTT, 1 mM PMSF, 10 WM leupeptin, 10 WM pepsta-
tin, 1 WM aprotinin, 5 WM okadaic acid, 10 WM sodium orthovana-
date, 0.1 mg/ml heparin and 0.32^0.64 Wg of GSK3L. The reaction
was started by the addition of ATP (¢nal concentration 3 mM) con-
taining 10 WCi of [Q-32P]ATP. Phosphorylation was terminated by
boiling in Laemmli sample bu¡er for 5 min.
2.3. Two dimensional phosphopeptide mapping of human tau
(wt, P301L, V337M and R406W)
Radiolabelled human tau (wt, P301L, V337M and R406W) in elec-
trophoresis sample bu¡er was resolved by 10% (w/v) acrylamide SDS^
PAGE, then transferred onto Immobilin P membrane (Millipore, UK)
at 15 V for 45 min. Protein was visualised by staining of the mem-
brane with 0.1% (w/v) amido black solution [30] and radiolabelled
protein identi¢ed by phosphorimage analysis on a Fujix Bas 1000
imager. The phosphorylated tau bands were excised, counted by Cer-
enkov radiation then destained in 200 Wl of 200 WM NaOH solution
for 2U30 min at 37‡C. Destained membrane was washed with dis-
tilled H2O then blocked in 0.04% (v/v) polyvinylpyrrolidone 40 in 100
mM acetic acid for 1 h at 37‡C. Membrane was washed again in
distilled H2O prior to placing in 200 Wl of 0.2 M NH4HCO3 pH 8.0
containing trypsin (1:20 (w/v) trypsin:tau) and incubated for V15 h
at 37‡C. A second addition of trypsin (1:20 (w/v) trypsin:tau) was
made at this point and the incubation continued for a further 4 h at
37‡C. Tryptic peptide solution was removed from the PVDF mem-
brane strip and prepared for phosphopeptide mapping analysis by
drying under vacuum on a Savant SC199 Speed-vac to remove all
of the water and NH4HCO3 pH 8.0 and then resuspended twice in
distilled H2O and twice in pH 1.9 electrophoresis bu¡er (water/acetic
acid/formic acid: 90/7.8/2.2 (v/v/v)), each time lyophilising the samples
to dryness. Each dried sample was resuspended in 5 Wl of pH 1.9
electrophoresis bu¡er and loaded onto a thin layer cellulose chroma-
tography plate (20U20 cm). Two dimensional separation was
achieved by electrophoresis at pH 1.9 for 1.25 h in the ¢rst dimension,
then, after air-drying, by ascending phospho-chromatography in the
second dimension (n-butanol/pyridine/acetic acid/water: 37.5/25/7.5/30
(v/v/v/v)) for 18 h. The plate was removed from the chromatography
tank, air-dried and then exposed to phosphorimage analysis and auto-
radiography at 370‡C to enable visualisation of phosphopeptides.
2.4. NanoES-MS analysis of phosphopeptide spots
Phosphopeptide spots were scraped from the thin layer chromatog-
raphy plates, the phosphopeptide constituents eluted in 20% (v/v)
acetonitrile in water and analysed by nanoES-MS as described pre-
viously [31].
3. Results
3.1. Expression and puri¢cation of wt, P301L, V337M and
R406W 2N4R tau
The locations of the three exonic missense FTDP-17 muta-
tions of tau used in this study are illustrated in Fig. 1A,B.
Two of the mutations lie within the microtubule binding do-
mains of the largest isoform of tau (P301L and V337M) whilst
the third mutation is found close to the C-terminus of the
protein (R406W). The P301L mutation is only found in four
repeat tau as this mutation occurs in exon 10 which is spliced
out during generation of three repeat tau mRNA. Wt 2N4R
tau and the three exonic FTDP-17 mutants, P301L, V337M
and R406W 2N4R tau forms, were expressed in E. coli as
described and all proteins puri¢ed in the exact same manner.
Fig. 2 illustrates a protogold-stained blot of the various puri-
¢cation stages for the wt 2N4R tau isoform. In all cases, the
tau protein was eluted from the Mono S anion exchange col-
umn at essentially the same part of the salt gradient (V250
mM NaCl), indicating that the single amino acid mutation
changes had little or no e¡ect on this physical property of
the individual tau proteins (lane 7).
3.2. In vitro phosphorylation of wt tau and the exonic FTDP-17
mutated tau proteins
Wt 2N4R tau and the P301L, V337M and R406W FTDP-
Fig. 1. FTDP-17 tau mutations and tau phosphorylation sites num-
bered according to the largest tau. A: Schematic diagram of the tau
gene from exon 9 to exon 13 showing the three FTDP-17 muta-
tions, P301L, V337M and R406W. B: Full-length 2N4R tau with
the serine and threonine phosphorylation sites found to be phos-
phorylated by GSK3L in this study (identi¢ed by nanoES-MS anal-
ysis of GSK3L phosphorylated 1N4R tau) and the positions of the
three missense FTDP-17 mutations relative to the phosphorylation
sites.
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17 mutant proteins were phosphorylated in vitro by the pro-
line-directed kinase GSK3L in the presence of radiolabelled
[Q-32P]ATP overnight at 30‡C. The labelled proteins were sep-
arated by 10% w/v acrylamide SDS^PAGE and then subjected
to two dimensional phosphopeptide mapping analysis follow-
ing trypsin digestion of the proteins as described. Individual
phosphopeptide spots were visualised by phosphorimage anal-
ysis. Fig. 3 compares the pattern of phosphopeptides found
for wt, P301L, V337M and R406W tau phosphorylated by
GSK3L. There were no di¡erences in the general phosphopep-
tide mapping patterns of wt, P301L and V337M 2N4R tau
(Fig. 3A^C), each consistently showing six well resolved spots.
However, the R406W tau phosphopeptide map demonstrated
clear di¡erences from the other three maps with at least two
major phosphopeptide spots being absent (Fig. 3D). To de-
termine the phosphopeptide constituents and the actual sites
of phosphorylation of each individual spot (numbered 1^6),
we used the previously identi¢ed sites found in 1N4R wt tau
as the peptide maps generated following GSK3L phosphory-
lation of the 1N4R and 2N4R wt tau isoforms were identical
(Fig. 4 and Table 1). Phosphopeptide spots 3 (residues 231^
240) and 6a (residues 386^404) and a second peptide compo-
nent of spot 6 (spot 6b) covering residues 191^209 were absent
from the R406W peptide map (Fig. 3D). The actual sites of
phosphorylation reduced were determined to be Thr231 and
Ser235 for spot 3 and Ser396, 400 and 404 for the ¢rst peptide
constituent of spot 6 (6a) and Ser195 and 199 for spot 6b
(Table 1). Interestingly, spot 5 (residues 226^240) is una¡ected
by the R406W mutation even though it includes phosphory-
lated Ser231 and at least one other phosphorylation site. Un-
fortunately to date we have been unable to identify the phos-
phopeptide constituents of spots 1 and 4 by nanoES-MS.
4. Discussion
The discovery of a group of diseases called the ‘tauopathies’
Fig. 2. Puri¢cation pro¢le of E. coli expressed wt tau (2N4R). Re-
combinant wt tau (2N4R) was puri¢ed from E. coli according to
the procedure described in Section 2. 10% (w/v) acrylamide SDS^
PAGE analysis of the puri¢cation fractions followed by transfer
onto nitrocellulose paper and protogold staining of the membrane
according to the manufacturer’s instructions is shown: lane 1, Mr
standards; lane 2, bacterial cell pellet (uninduced); lane 3, bacterial
cell pellet (induced); lane 4, sonication supernatant; lane 5, heat/sta-
ble supernatant; lane 6, 45% ammonium sulphate precipitate and
lane 7, Mono S puri¢ed fraction.
Fig. 3. Two dimensional phosphopeptide map analysis of the phosphorylation of recombinant wt, P301L, V337M and R406W tau (2N4R) by
GSK3L. 1^2 Wg of wt, P301L, V337M and R406W tau (2N4R) was phosphorylated by GSK3L in the presence of [Q-32P]ATP and two dimen-
sional phosphopeptide mapping analysis performed as described in Section 2. Identical phosphopeptide maps were generated with the wt,
P301L and V337M forms of tau. However, phosphopeptide spots 3 and 6a and 6b were absent from the R406W phosphopeptide mapping
analysis.
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in which the primary pathological lesion is an aggregation of
hyperphosphorylated tau into ¢lamentous forms led us to in-
vestigate the e¡ects of various mutations of the tau gene
found associated with FTDP-17 on the in vitro phosphoryla-
tion of the recombinant 2N4R tau isoform by GSK3L. We
were able to directly monitor changes in sites of phosphory-
lation of wt, P301L, V337M and R406W tau by GSK3L using
the highly sensitive techniques of two dimensional phospho-
peptide mapping and nanoES-MS.
Several recent reports in cellular systems [25,26,32] using
Western blotting to monitor changes in tau phosphorylation
surprisingly suggested that the R406W mutation actually re-
sults in a lower state of phosphorylation of tau protein com-
pared to the wt protein, particularly at the PHF-1 (Ser396 and
Ser404) and AT180 sites (Thr231 and Ser235). We have con-
¢rmed these earlier ¢ndings in this paper where we clearly
demonstrate that only the R406W mutant tau peptide map
shows a reduced number of phosphopeptide spots (spots 3
and 6a and 6b absent) when compared to the wt, P301L
and V337M phosphopeptide maps. One would have expected
at least one di¡erence in the R406W phosphopeptide map
compared to the other tau proteins analysed in this study.
Phosphopeptide 6a covering residues 386^406 would be af-
fected by the Arg to Trp mutation, resulting in the loss of
its C-terminal trypsin cleavage site, a central feature of the
two dimensional phosphopeptide mapping analysis. The re-
moval of this potential trypsin cleavage site results in the
generation of a very large C-terminal tryptic peptide covering
residues 386^437. A peptide of this size would probably be
expected to remain close to the origin of separation of the
sample in this analytical procedure. However, it was di⁄cult
to determine whether this peptide had indeed remained at or
near the origin of separation as there was always much poorly
resolved material in this region of the plate (Fig. 3). It is
however quite likely that the R406W mutation markedly re-
duced phosphorylation at serines 396, 400 and 404 as previ-
ously reported above [25,26,32]. Furthermore, in a recent
study by Vogelsberg-Ragaglia et al. [35] they illustrated by
immunoblotting a reduction in phosphorylation at Ser396
and Ser404 in stably expressing CHO cells harbouring the
R406W mutant tau but no other changes in phosphorylation.
Interestingly, in addition to spot 6a being absent from the
R406W peptide map, spot 6b (residues 191^209, phosphory-
lated at Ser195 and 199) and spot 3 (residues 231^240, phos-
phorylated at Thr231 and Ser235) were also missing. This
potential loss of phosphorylation at Thr231 and Ser235 is
consistent with the Western blotting analysis of cell lysates
prepared from transiently transfected CHO cells [25] and sta-
bly expressing CHO cells harbouring the R406W tau mutant
protein [26]. However this technique reveals that spot 5 (res-
idues 226^240), phosphorylated at Ser231, plus at least one
other site is una¡ected by the R406W mutation. Potential
reasons for this discrepancy are that in vitro phosphorylated
wt 2N4R tau has the potential to exist in at least two di¡erent
conformational states that a¡ect trypsin cleavage. This selec-
tive cleavage results in the generation of either spot 3 or spot
5 on the wt map. The R406W mutation could shift the equi-
librium between conformations so as to further bias trypsin
cleavage, resulting in the exclusive production of spot 5 over
spot 3 on the R406W map. Spot 5 could also contain at least
one other peptide component that is una¡ected by the R406W
mutation. Finally, the mutation may reduce phosphorylation
Fig. 4. Two dimensional phosphopeptide map analysis of the phosphorylation of recombinant 1N4R and wt 2N4R tau by GSK3L. 1^2 Wg of
1N4R and wt 2N4R tau were phosphorylated by GSK3L in the presence of [Q-32P]ATP and two dimensional phosphopeptide mapping analysis
performed as described in Section 2. Identical phosphopeptide maps were generated with these two tau isoforms.
Table 1
Identi¢cation of phosphopeptides and sites of phosphorylation of 2N4R tau after in vitro phosphorylation by GSK3L
Phosphopeptide spot number Residues Sequence Site(s) identi¢ed
2 210^221 SRTpPSLPTpPPTR 212, 217
3a 231^240 TpPPKSpPSSAK 231, 235
5 226^240 VAVVRTpPPKSPSSAK (+1 p) 231, (235, 237 or 238)
6aa 386^406 TDHGAEIVYKSpPVVSpGDTSpPR 396, 400, 404
6ba 191^209 SGDRSpGYSSpPGSPGTPGSR 195, 199
2N4R tau phosphopeptides and sites of phosphorylation were assigned from the equivalent spots on 1N4R tau (data not shown).
aRepresents the spots missing from the R406W peptide map. Sp and Tp indicate phosphorylated serine or threonine residues.
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at Ser235 only, altering the migration pattern of spot 3. This
could result in its co-migration with an una¡ected phospho-
peptide. In this interpretation spot 5, potentially phosphory-
lated at two other sites, remains una¡ected by the mutation.
Although it is possible for the R406W mutation to alter the
activity of trypsin via conformational changes, this detailed
chemical analysis of tau phosphorylation has enabled us to
demonstrate that the R406W mutation of tau does in fact
cause changes in phosphorylation distant from the mutational
site. Clearly, the change of a basic amino acid residue Arg for
a hydrophobic amino acid Trp results in a change in the
conformation of this tau protein molecule which not only
renders sites of phosphorylation close to the mutation inac-
cessible (Ser396, 400 and 404) to GSK3L but also sites of
phosphorylation far removed from the mutation site
(Ser195, 199 and 235 and Thr231). The fact that the in vitro
phosphorylation at Thr231 and Ser235 of the R406W mutant
tau was similar to that observed in cells [25,26] demonstrates
that this e¡ect of the R406W mutation on the conformation is
robust and not just an in vitro observation.
The reduced phosphorylation of tau by the R406W mutant
is not the only experimental system where this mutant behaves
di¡erently from other known FTDP-17 mutants. In a number
of in vitro and cellular assays when compared to wt tau and
other FTDP-17 mutants, the R406W tau protein only shows a
small loss of function [25,31,33,34]. All of the ¢ndings to date
may contribute to why this mutation causes late onset of
disease relative to other known FTDP-17 mutants and may
account for the relatively mild phenotype found in families
with this mutation.
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